DCM
RPRX icon

Davis Capital Management’s Royalty Pharma RPRX Stock Holding History

Davis Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673 Buy
12
+11
+1,100% +$573 ﹤0.01% 559
2026
Q1 		$48 Hold
1
– – ﹤0.01% 582
2025
Q4 		$39 Sell
1
-5
-83% -$191 ﹤0.01% 599
2025
Q3 		$212 Buy
+6
New +$217 ﹤0.01% 567

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Davis Capital Management's RPRX Position: Q2 2026 in Review

Davis Capital Management increased its Royalty Pharma (RPRX) stake by 1,100% in Q2 2026, buying an estimated $573 and bringing the position to 12 shares worth $673. The position accounts for ﹤0.01% of the portfolio, ranked #559.

Davis Capital Management first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Davis Capital Management held 12 shares of Royalty Pharma worth $673 as of Q2 2026.
  • Davis Capital Management bought 11 Royalty Pharma shares in Q2 2026, an estimated $573.
  • Royalty Pharma made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #559 holding.
  • Davis Capital Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.